BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 26893551)

  • 1. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
    Wedzicha JA; Calverley PM; Seemungal TA; Hagan G; Ansari Z; Stockley RA;
    Am J Respir Crit Care Med; 2008 Jan; 177(1):19-26. PubMed ID: 17916806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
    Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.